Pediatric neuro-Behçet's disease responsive to adalimumab

Pediatr Neurol. 2010 Oct;43(4):291-3. doi: 10.1016/j.pediatrneurol.2010.04.021.

Abstract

Neurologic manifestations of Behçet's disease (neuro-Behçet's disease) are uncommon, but may cause patients significant morbidity and mortality. Neuro-Behçet's disease is chronic and may be refractory to treatment. We report on a 12-year-old girl with neuro-Behçet's disease that responded to standard doses of subcutaneous adalimumab.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Behcet Syndrome / pathology
  • Behcet Syndrome / therapy*
  • Brain / pathology*
  • Child
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Adalimumab